PanOptica Raises $30M Series A for AMD Eye Drop Candidate

Wall, Tom
January 2011
BioWorld Today;1/4/2011, Vol. 22 Issue 2, p1
The article reports on the Series A financing raised by Mount Arlington, New Jersey-based PanOptica Inc. for its eye drop treatment for neovascular age-related macular degeneration (AMD). A brief background on the competition in the wet AMD market is provided. The financing round coincided with the licensing of exclusive ophthalmic rights to PAN-90806 from OSI Pharmaceuticals Inc in exchange for cash, equity interest and royalties. PanOptica President Paul Chaney believes in the potential for innovation in ophthalmology therapies.


Related Articles

  • Phase IV Macugen Maintenance Trial Launched.  // Review of Ophthalmology;Jul2006 Part 1 of 2, Vol. 13 Issue 7, p10 

    The article reports on the launch of a Phase IV trial by OSI Pharmaceuticals Inc. and Pfizer Inc. that will explore the safety and efficacy of Macugen as a maintenance therapy for patients who have received neovascular Age-Related Macular Degeneration treatment and experience improvement in...

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...

  • At OSI, a $935M poke in the Eye(tech). Harrell, Jeremy // Long Island Business News (7/1993 to 5/2009);11/10/2006, Vol. 53 Issue 51, p5A 

    The article reports developments surrounding the $935-million investment in cash and stock of OSI Pharmaceuticals Inc. to acquire the macular degeneration drug called Macugen from Eyetech Pharmaceuticals Inc. in Melville, New York in November 2005. At that time, analysts and stockholders...

  • OSI/Eyetech announces management changes.  // Ophthalmology Times;8/1/2006, Vol. 31 Issue 15, p10 

    The article reports on changes in the management of OSI Pharmaceuticals' OSI/Eyetech Pharmaceuticals business in the U.S. Paul G. Chaney has been promoted as executive vice president of OSI Pharmaceuticals and president of OSI/Eyetech. OSI Pharmaceuticals executive vice president and OSI/Eyetech...

  • Potential AMD treatment: PanOptica licenses VEGF inhibitor.  // Ophthalmology Times;1/15/2011, Vol. 36 Issue 2, p8 

    The article reports on the move of PanOptica Inc. to raise 30 million dollars to finance its successful licensing of exclusive global ophthalmic rights to vascular endothelial growth factor (VEGF).

  • Optherion's Protein Replacement For AMD Nabs $37M Series A. Morrison, Trista // BioWorld Today;10/10/2007, Vol. 18 Issue 197, p1 

    The article reports on the amount raised by New Haven, Connecticut-based Optherion Inc. from a Series A financing. The company raised $37 million to advance its preclinical research with a new approach to diagnosing and treating age-related macular degeneration (AMD). The company is pursuing the...

  • FINANCINGS ROUNDUP.  // BioWorld Today;1/7/2008, Vol. 19 Issue 4, p7 

    This section offers business finance-related news briefs. Follica Inc. has raised $5.5 million in a Series A round led by Interwest Partners. Helicos BioSciences Corp. closed a senior secured credit facility with GE Healthcare Financial Services. Meanwhile, OSI Pharmaceuticals Inc. priced a...

  • Earnings Roundup.  // BioWorld Today;7/30/2008, Vol. 19 Issue 147, p3 

    The article reports on the decrease in the total revenue of QLT Inc. for the quarter ending June 30, 2008. The decrease was attributed to the drop in worldwide sales of age-related macular degeneration treatment Visudyne. The company reported a loss per share of 10 cents and ended the...

  • Financings Roundup.  // BioWorld Today;4/10/2008, Vol. 19 Issue 70, p6 

    The article reports on a $12 million round of financing completed by Potentia Pharmaceuticals Inc. of Louisville, Kentucky. The fund will be used to complete the company's Phase I study of POT-4, a potential treatment for age-related macular degeneration, and move it into Phase II. The drug is a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics